Skip to Content

Mozobil Approval History

FDA Approved: Yes (First approved December 15, 2008)
Brand name: Mozobil
Generic name: plerixafor
Company: Genzyme Corporation
Treatment for: Bone Marrow Transplantation

Mozobil (plerixafor) is a small molecule CXCR4 chemokine receptor antagonist used in combination with granulocyte-colony stimulating factor to mobilize hematopoietic stem cells to the bloodstream for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma and multiple myeloma.

Development History and FDA Approval Process for Mozobil

DateArticle
Dec 16, 2008Approval FDA Approves Genzyme's Mozobil
Sep 23, 2008Genzyme Announces FDA Priority Review for Mozobil New Drug Application
Jun 17, 2008Genzyme Files Applications for Approval of Mozobil in the United States and Europe

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide